This week on IPWatchdog Unleashed, I spoke with Brent Bellows, a partner with Knowles Intellectual Property Strategies (KIPS). We discussed a variety of issues including Hatch-Waxman, Orange Book listings, paragraph IV certifications, skinny labels, generic entry, clinical trial costs, regulatory exclusivity, and the enormous financial risk associated with bringing new drugs to market. Gene and Brent explore the tension between public demand for lower drug prices and the need for durable incentives that make high-risk drug development economically viable, particularly for oncology, Alzheimer’s, Parkinson’s, antibiotic resistant bacteria, and other difficult-to-treat conditions. The episode closes with a broader innovation-policy message: patents are not a peripheral feature of drug development—they are a core operating asset that enables private-sector investment, supports breakthrough therapies, and ultimately drives the availability of future generic medicines.
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday in a precedential decision authored by Judge Lourie affirmed a district court’s ruling determining certain claims of Enviro Tech Chemical Services, Inc.’s patent for a method of poultry treatment indefinite. Enviro Tech’s U.S. Patent No.10,912,321is titled “Methods of Using Peracetic Acid to Treat Poultry in a Chill Tank During Processing.” Enviro Tech sued Safe Foods Corp. for infringement of a number of claims of the patent in the U.S. District Court for the Eastern District of Arkansas.
On April 30, the Office of the U.S. Trade Representative (USTR) released this year’s Special 301 Report, which surveys the effectiveness of intellectual property (IP) rights and enforcement abroad and identifies foreign nations where IP protections are uncertain or disregarded. The 2026 report marks the first time in 13 years that a Priority Foreign Country (PFC) has been named, with Vietnam being identified as a PFC for persistent failures to address several long-standing IP concerns. The USTR has also added the European Union (EU) to the Special 301 Report’s Watch List, the first time since 2006 that the continental government has been identified for IP-related concerns in addition to individual European nations.
The U.S. Patent and Trademark Office (USPTO) issued a significant Decision on Remand on Monday, April 27, 2026, clarifying when estoppel under 35 U.S.C. § 315(e)(1) attaches and—critically—what it means to “request” a proceeding “before the Office.” The ruling arises from an increasingly common set of circumstances—HID had initially filed an inter partes review (IPR) against CPC Patent Technologies’ U.S. Patent No. 9,665,705, and subsequently requested ex parte reexamination requests of that same patent. Monday’s decision clarifies that a party is estopped from “requesting” ex parte reexam at the moment the IPR final written decision issues when the USPTO has yet to order ex parte reexam.
In this episode of IPWatchdog Unleashed, I speak with Matt Johnson, Co-Chair of the PTAB Practice at Jones Day, and we take an in-depth look at the Patent Trial and Appeal Board (PTAB) nearly a decade and a half after its launch. Johnson and I discuss the ongoing PTAB reset at the United States Patent and Trademark Office (USPTO) and suggest practical fixes for a better, reengineered PTAB. The majority of the conversation is devoted to concrete, targeted reform suggestions that would lead to a better functioning PTAB and more streamlined IPR review system. Instead of abstract complaints, Johnson proposes narrowing PGR estoppel to encourage early challenges, moving IPR estoppel to the point of institution to eliminate gamesmanship, separating institution decisions from full merits adjudication to reduce confirmation bias, and rethinking quiet-title concepts to better align notice to implementers with settled expectations of patent owners.
Arnold & Porter is a leading international law firm with offices across the United States, Europe, and Asia. The firm delivers sophisticated regulatory, litigation, and transactional services to clients across a wide range of industries. Arnold & Porter is seeking a Senior Manager of IP Prosecution to join its Washington, DC office. This role provides firmwide leadership for the Intellectual Property Prosecution function, overseeing patent and trademark operations and ensuring the delivery of efficient, high-quality support to attorneys and clients.
I keep hearing the same thing from patent professionals across the industry—inside companies, inside law firms, and even from investors. Patent budgets are shrinking, expectations are rising, and nobody seems willing to admit what that combination actually means.
This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European Union as a Watch List nation for IP-related issues; Senators Dick Durbin (D-IL) and Maria Cantwell (D-WA) publicly oppose the Trump Administration’s decisions to cut federal funding for science and upend the National Science Board; and more.
The University of North Carolina at Charlotte brought together leaders from government, academia, industry, and the defense community for its 2026 Invention of the Year Awards, an evening that showcased the university’s growing role as a national engine of innovation, commercialization, and technological impact.
Whether or not the United States Patent and Trademark Office (USPTO) wants to admit it, over most of the last generation there has been a secret examination docket. Not surprisingly, such a secret examination docket is strictly prohibited by federal law. A newly filed joint status report in Morinville v. USPTO brings this issue to the fore and underscores the lack of transparency and accountability of secret internal patent review programs at the USPTO. Procedurally, the latest filing seeks to expose the USPTO shadow docket through a new round of discovery, which is currently being considered by the United States District Court for the District of Columbia.
This week on IPWatchdog Unleashed, I had the pleasure of speaking with Deborah Farone, founder of Farone Advisors, former Chief Marketing Officer of Cravath, Swain & Moore, and author of Breaking Ground: How Successful Women Lawyers Build Thriving Practices. Our conversation focused on how lawyers—particularly in highly technical fields like intellectual property—can build thriving practices through disciplined, strategic business development. The discussion underscores that business development is a skill, not an innate personality trait. Even introverted attorneys can succeed by taking incremental steps, practicing authentic communication, and focusing on listening rather than selling.
The UK Supreme Court today issued a landmark judgment on AI patentability that is likely to impact all software patents going forward. The decision in Emotional Perception v. Comptroller General of Patents, Designs and Trade Marks primarily held that the approach taken in Aerotel Ltd v Telco Holdings Ltd [2006] EWCA Civ 1371; [2007] Bus LR 634; [2007] RPC 7 (Aerotel) should no longer be followed. Under Aerotel, courts and examiners consider a four-step test for assessing whether a claim is excluded from patent eligibility: 1) properly construe the claim, 2) Identify the actual/ alleged contribution, 3) Ask whether the contribution is excluded and 4) check if the contribution is technical.
On Tuesday, news reports indicated that U.S. Senators Adam Schiff (D-CA) and John Curtis (R-UT) introduced the Copyright Labeling and Ethical AI Reporting (CLEAR) Act into Congress. If enacted as drafted, the bill would establish mandatory reporting requirements for companies developing artificial intelligence (AI) models that are trained using original works that are protected under U.S. copyright law, and would create an additional cause of action for copyright owners alleging that generative AI developers failed to give such notice with respect to their works.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates